The global market for Cancer / Tumor Profiling is estimated at US$10.3 Billion in 2023 and is projected to reach US$19.8 Billion by 2030, growing at a CAGR of 9.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.
The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies. Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Immunoassays Technology segment, which is expected to reach US$6.2 Billion by 2030 with a CAGR of a 9.3%. The Next Generation Sequencing Technology segment is also set to grow at 10.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.7 Billion in 2023, and China, forecasted to grow at an impressive 10.6% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cancer / Tumor Profiling Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer / Tumor Profiling Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cancer / Tumor Profiling Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Caris Life Sciences, Genomic Health, Inc., Helomics Corporation, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 55 Featured):
- Caris Life Sciences
- Genomic Health, Inc.
- Helomics Corporation
- HTG Molecular Diagnostics, Inc.
- Illumina, Inc.
- Nanostring Technologies, Inc.
- NeoGenomics Laboratories, Inc.
- Oxford Gene Technology
- Qiagen NV
- Ribomed Biotechnologies, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Caris Life Sciences
- Genomic Health, Inc.
- Helomics Corporation
- HTG Molecular Diagnostics, Inc.
- Illumina, Inc.
- Nanostring Technologies, Inc.
- NeoGenomics Laboratories, Inc.
- Oxford Gene Technology
- Qiagen NV
- Ribomed Biotechnologies, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 376 |
| Published | November 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 10.3 Billion |
| Forecasted Market Value ( USD | $ 19.8 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
